RU2694361C3 - Композиция слабительного средства - Google Patents

Композиция слабительного средства

Info

Publication number
RU2694361C3
RU2694361C3 RU2003109622A RU2003109622A RU2694361C3 RU 2694361 C3 RU2694361 C3 RU 2694361C3 RU 2003109622 A RU2003109622 A RU 2003109622A RU 2003109622 A RU2003109622 A RU 2003109622A RU 2694361 C3 RU2694361 C3 RU 2694361C3
Authority
RU
Russia
Prior art keywords
composition
fatty acid
medium chain
amount
triglyceride
Prior art date
Application number
RU2003109622A
Other languages
English (en)
Russian (ru)
Other versions
RU2694361C9 (ru
RU2694361C2 (ru
RU2003109622A (ru
Original Assignee
Сукампо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2694361(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сукампо Аг filed Critical Сукампо Аг
Publication of RU2003109622A publication Critical patent/RU2003109622A/ru
Application granted granted Critical
Publication of RU2694361C2 publication Critical patent/RU2694361C2/ru
Publication of RU2694361C9 publication Critical patent/RU2694361C9/ru
Publication of RU2694361C3 publication Critical patent/RU2694361C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
RU2003109622A 2000-09-05 2001-09-04 Композиция слабительного средства RU2694361C3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
US09/655,760 2000-09-05
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (4)

Publication Number Publication Date
RU2003109622A RU2003109622A (ru) 2004-09-10
RU2694361C2 RU2694361C2 (ru) 2019-07-12
RU2694361C9 RU2694361C9 (ru) 2019-12-25
RU2694361C3 true RU2694361C3 (ru) 2020-07-20

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003109622A RU2694361C3 (ru) 2000-09-05 2001-09-04 Композиция слабительного средства

Country Status (25)

Country Link
US (7) US6414016B1 (cg-RX-API-DMAC7.html)
EP (2) EP1315485B1 (cg-RX-API-DMAC7.html)
JP (3) JP2004508327A (cg-RX-API-DMAC7.html)
KR (2) KR100918223B1 (cg-RX-API-DMAC7.html)
CN (1) CN100335049C (cg-RX-API-DMAC7.html)
AR (2) AR030609A1 (cg-RX-API-DMAC7.html)
AT (1) ATE476975T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001282615B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0114042B8 (cg-RX-API-DMAC7.html)
CA (1) CA2419741C (cg-RX-API-DMAC7.html)
CZ (1) CZ304740B6 (cg-RX-API-DMAC7.html)
DE (2) DE60131547T2 (cg-RX-API-DMAC7.html)
DK (2) DK1857105T3 (cg-RX-API-DMAC7.html)
ES (2) ES2296786T3 (cg-RX-API-DMAC7.html)
HU (1) HU229319B1 (cg-RX-API-DMAC7.html)
IL (2) IL154534A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001959A (cg-RX-API-DMAC7.html)
NL (1) NL300757I2 (cg-RX-API-DMAC7.html)
NO (1) NO332701B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524401A (cg-RX-API-DMAC7.html)
PT (2) PT1315485E (cg-RX-API-DMAC7.html)
RU (1) RU2694361C3 (cg-RX-API-DMAC7.html)
TW (1) TWI305147B (cg-RX-API-DMAC7.html)
WO (1) WO2002020007A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301673B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
KR101164838B1 (ko) * 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101048163A (zh) * 2004-09-02 2007-10-03 苏坎波公司 用于治疗胃肠道疾病的前列腺素衍生物
AU2006209072B2 (en) 2005-01-27 2011-02-24 Sucampo Ag Method and composition for treating central nervous system disorders
DE602006018583D1 (de) 2005-03-04 2011-01-13 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
ES2371658T3 (es) * 2005-04-12 2012-01-05 Sucampo Ag Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
CA2819844C (en) * 2006-02-07 2015-09-15 R-Tech Ueno, Ltd. Prostaglandin derivatives
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
DK2349250T3 (en) * 2008-10-31 2017-07-03 Lipid Pharmaceuticals Ehf Fatty acids for use as a medicament
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP5502106B2 (ja) 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
EP2516412A4 (en) * 2009-12-18 2013-05-29 Apotex Pharmachem Inc PROCESS FOR CLEANING LUBIPROSTON
US8785663B2 (en) 2010-01-28 2014-07-22 Alfredo Paul Ceccarelli Polymorphic forms of Lubiprostone
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
PT2983667T (pt) 2013-04-12 2019-07-11 Ardelyx Inc Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
CN110494721B (zh) * 2017-04-20 2022-06-24 株式会社岛津制作所 分光光度计
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (cg-RX-API-DMAC7.html) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ATE78465T1 (de) 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
DE69910183T2 (de) 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
JP2004504443A (ja) * 2000-07-14 2004-02-12 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン コンパートメントを有する中空体
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
NZ524401A (en) 2004-08-27
PT1857105E (pt) 2010-10-08
EP1857105A3 (en) 2008-03-05
DE60131547T2 (de) 2008-10-23
IL154534A0 (en) 2003-09-17
IL154534A (en) 2010-04-29
JP2009114217A (ja) 2009-05-28
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
RU2694361C9 (ru) 2019-12-25
CN100335049C (zh) 2007-09-05
EP1315485A1 (en) 2003-06-04
ATE476975T1 (de) 2010-08-15
JP2004508327A (ja) 2004-03-18
US20140235665A1 (en) 2014-08-21
US20120022152A1 (en) 2012-01-26
AR100291A2 (es) 2016-09-28
US8748454B2 (en) 2014-06-10
BRPI0114042B1 (pt) 2016-11-08
NO332701B1 (no) 2012-12-10
AU8261501A (en) 2002-03-22
NO20030996L (no) 2003-05-02
DK1857105T3 (da) 2010-09-20
BRPI0114042B8 (pt) 2021-05-25
BR0114042A (pt) 2003-07-22
CZ304740B6 (cs) 2014-09-17
US20120237598A1 (en) 2012-09-20
MXPA03001959A (es) 2003-06-24
EP1857105B1 (en) 2010-08-11
CN1655776A (zh) 2005-08-17
HU229319B1 (en) 2013-10-28
PT1315485E (pt) 2008-01-23
US8071613B2 (en) 2011-12-06
DK1315485T3 (da) 2008-03-03
ES2347697T3 (es) 2010-11-03
US20050222195A1 (en) 2005-10-06
US6610732B2 (en) 2003-08-26
AR030609A1 (es) 2003-08-27
JP2009286806A (ja) 2009-12-10
TWI305147B (en) 2009-01-11
NO20030996D0 (no) 2003-03-04
ES2296786T3 (es) 2008-05-01
CA2419741A1 (en) 2002-03-14
HUP0302422A3 (en) 2005-02-28
KR20080091278A (ko) 2008-10-09
KR100901102B1 (ko) 2009-06-08
KR20030029919A (ko) 2003-04-16
HUP0302422A2 (hu) 2003-10-28
AU2001282615B2 (en) 2006-06-22
DE60142810D1 (de) 2010-09-23
US20030040528A1 (en) 2003-02-27
US6414016B1 (en) 2002-07-02
EP1315485B1 (en) 2007-11-21
RU2694361C2 (ru) 2019-07-12
NL300757I1 (cg-RX-API-DMAC7.html) 2015-12-29
DE60131547D1 (de) 2008-01-03
US8114890B1 (en) 2012-02-14
NL300757I2 (cg-RX-API-DMAC7.html) 2015-12-29
KR100918223B1 (ko) 2009-09-21
ZA200301673B (en) 2003-11-26
US20030216465A1 (en) 2003-11-20
CA2419741C (en) 2010-11-30
WO2002020007A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
RU2694361C3 (ru) Композиция слабительного средства
RU2003109622A (ru) Композиция слабительного средства
RU2002133868A (ru) Каннабиноидные лекарственные средства
RU98107654A (ru) Композиция для перорального применения против образования зубного налета
RU96117038A (ru) Композиция для обработки полости рта
CA2263203A1 (en) 3,6-ketal and enol ether macrolide antibiotics
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
CA2413889A1 (en) Wipe with improved cleansing
KR870007118A (ko) 광학적으로 순수한 화합물 및 그의 제조 방법
MXPA03010510A (es) Composicion catartica.
RU2002121636A (ru) Производные индола в качестве антагонистов рецепторов мср-1
RU2001118219A (ru) Ингибитор ангиогенеза
RU2002110952A (ru) Крем "Брамизил" противогрибкового действия
RU93019277A (ru) Раствор для защиты и лечения заболеваний и повреждения роговицы "визитон"
KR970020112A (ko) 결명자 추출물의 제조방법과 이들로된 항산화, 프리라디칼소거, 항돌연변이제 및 안(眼) 노화 방지 안질환예방제
RU95111378A (ru) Фармацевтические композиции 3-замещенных 2-оксиндол-1-карбоксамидов, способ ингибирования активации коллагеназы, способ вызова анальгезирующей реакции, способ лечения воспалительных заболеваний
RU97102193A (ru) Способ получения стоматологических пластинок из комбинированного трансплантата
RU2003114829A (ru) Гинекологические овули с дибунолом для лечения воспалительных заболеваний
RU2000121193A (ru) Средство для местного лечения язвенной болезни желудка и двенадцатиперстной кишки
RU95118080A (ru) Лечебно-профилактический гигиенический противогерпетический крем
KR910004620A (ko) 위궤양 치료제
KR910002455A (ko) 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용
KR970032878A (ko) 홍경천 추출물을 함유하는 혈중 알콜농도 저하용 조성물
RU95117331A (ru) Композиция наружного применения
RU2000106183A (ru) Препарат, обладающий антимикробным и регенерирующим действием

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 18-2006 FOR TAG: (43)

RZ4A Other changes in the information about an invention
TH4A Reissue of patent specification
ND4A Extension of patent duration

Effective date: 20200720